TLR2 has been demonstrated to affect cancer cell behaviors by activating several downstream signaling pathways, including NF-kB, PI3K/Akt and Wnt/β-catenin pathways (Liu et al., 2018; Chen et al., 2019). The gene discussed is NFKB1; the disease is cancer.